|Bid||84.60 x 1300|
|Ask||84.61 x 1000|
|Day's range||84.40 - 85.22|
|52-week range||66.10 - 87.35|
|Beta (3Y monthly)||0.32|
|PE ratio (TTM)||23.68|
|Earnings date||29 Oct 2019|
|Forward dividend & yield||2.20 (2.58%)|
|1y target est||96.33|
Glaxo's (GSK) SLE drug Benlysta gets a favorable CHMP opinion that recommends an approval for intravenous formulation in pediatric patients.
Merck's (MRK) new HIV drugs, Pifeltro and Delstrigo, get FDA nod for use in treatment-experienced adults living with HIV-1 who are virologically suppressed.
CHMP gives positive opinion to add cardiovascular risk reduction data from the REWIND outcomes study on the label of Lilly's (LLY) diabetes medicine, Trulicity.
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio in combination with Inlyta gets positive CHMP recommendation for first-line treatment of advanced kidney cancer.
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce a non-brokered private placement (the “Private Placement”) of up to approximately 8,571,428 common shares in the capital of the Company for gross proceeds of up to approximately C$600,000 at a price per common share of C$0.07. The closing of the Offering is scheduled to occur on or about September 26, 2019. All securities issued under the Private Placement will be subject to a hold period expiring 4 months plus 1 day following the closing date of the Private Placement.
Approvals Based on Findings from the Phase 3 DRIVE-SHIFT Trial Evaluating a Switch to DELSTRIGO
Material information is being presented concurrent with this press release at 9:35am Eastern Time at the Next Gen Immuno-Oncology Congress. Publicly-traded securities of BriaCell Therapeutics Corp. (BCT.V) (BCTXF) will remain halted for the duration of CEO Dr. Williams’ presentation. Robust responder experienced a highly remarkable reduction in breast cancer tumors in the adrenal gland and the outer lining of the brain – tumors that had metastasized to areas outside of her breasts. Prior to the Combination Study of Bria-IMT™ with KEYTRUDA®, she had failed prior regimens with 16 agents (13 chemotherapy and 3 hormonal).
Merck (MRK) receives accelerated approval for label expansion of Keytruda in combination with Lenvima for treating certain types of endometrial carcinoma. Its Ebola vaccine BLA gets priority review.
Combination Treatment Approved for Patients with Advanced Endometrial Carcinoma That Is Not Microsatellite Instability-High or Mismatch Repair Deficient , Who Have Di
The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.
J&J's (JNJ) sBLA seeking approval for Tremfya for active psoriatic arthritis is based on data from the phase III DISCOVER 1 and 2 studies.
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted priority review for Merck’s investigational Ebola vaccine (V920), under review for the prevention of disease caused by the Ebola Zaire virus. In July 2016, the FDA granted Breakthrough Therapy Designation to V920.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
The FDA approves new warnings about inflammation risk to be added to labels of Pfizer's (PFE) Ibrance, Eli Lilly's (LLY) Verzenio and Novartis' (NVS) Kisqali.
BERKELEY, Calif., Sept. 16, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in.
Roche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive early breast cancer.
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its NMOSD drug in a phase III study.
Reuters asked a U.S. judge on Thursday to unseal documents filed in court regarding potential risks associated with Propecia, Merck & Co's popular baldness drug. The motion was filed in federal court in Brooklyn, New York, after a Reuters article on Wednesday revealed accusations that Merck did not fully disclose on Propecia’s label the incidence and duration of sexual dysfunction in men who took Propecia in clinical trials.
While the broader stock market is expected to move higher, momentum investing will likely take charge as investors seek higher returns in a short span.